Skip To Main Content
Masae Kakubari on Muck Rack

Masae Kakubari

As seen in: Clinical Therapeutics
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Masae

Contact Masae, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment

|
By Yoshinobu Nakamaru, Masae Kakubari, Kaori Yoshida, Makoto Akimoto
| Clinical Therapeutics Verified
Highlights • Renal impairment did not significantly affect edaravone PK in Japanese patients. • Edaravone sulfate conjugate is a substrate for human organic anion transporters. • Reduced transporters may hypothetically increase sulfate conjugate levels. • Edaravone dosage adjustments may not be required in mild to moderate renal impairment.
Open in Who Shared Issue with article?

Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning

|
By Kaori Yoshida, Makoto Akimoto, Yoshinobu Nakamaru, Masae Kakubari
| Clinical Therapeutics Verified
Highlights • Hepatic impairment had no effect on edaravone PK in Japanese and white subjects • There were no notable safety concerns with edaravone administration • Edaravone dosage adjustments are unlikely to be needed in hepatic impairment • Edaravone PK did not differ in Japanese and white subjects after IV administration Abstract Purpose Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic...
Open in Who Shared Issue with article?
See all 2 articles